[EN] SUBSTITUTED OXADIAZOLIDINEDIONES ALS PAI-1 INHIBITORS<br/>[FR] OXADIAZOLIDINEDIONES SUBSTITUES UTILISES COMME INHIBITEURS DES ALS PAI-1
申请人:WYETH CORP
公开号:WO2005030203A1
公开(公告)日:2005-04-07
The present invention relates generally to substituted oxadiazolidinediones of the Formula (I); wherein R1 is hydrogen or -(CH2)nCOOH; n is an integer from 1 to 3; X is Formula (A), Formula (B), Formula (C) or Formula (D); as inhibitors of PAI-1.
A pharmaceutical agent having GPR40 receptor agonistic action, particularly a compound which is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus. The present inventors have examined a compound having GPR40 receptor agonistic action, confirmed that an oxadiazolidinedione compound which has a substituent such as a benzyl group, etc. linked with a substituent such as a phenyl group, etc. through a linker at the 2-position of an oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof has an excellent GPR40 agonistic activity, and thus completed the invention. The oxadiazolidinedione compound has excellent insulin secretagogue action and anti-hyperglycemic action, and therefore can be used as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
[Problem] A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided.
[Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.
2-Arylmethyl-1,2,4-oxadiazolidine-3,5-diones can be prepared in a single step by the regiospecific alkylation of 1,2,4-oxadiazolidine-3,5-dione with substituted benzyl halides.